A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of MK-0941 in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Insulin

After 20 weeks, to assess the effect of treatment with MK-0941 compared with placebo on A1C when added to basal insulin.